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Implantable cardioverter-defibrillators have been widely
used •to prevent sudden cardiac death. Rapid development of
defibrillator technology and its efficacy in aborting malignant
ventricular arrhythmias have dramatically improved man-
agment and prognosis of patients with ventricular tachycar-
dia or ventricular fibrillation and survivors of cardiac arrest
(1-7) . Recently, the use of lead systems that do not require
thoracotomy has been advocated to minimize the postoper-
ative morbidity and mortality associated with thoracotomy
for placement of the defibrillating electrodes (8-16). Nontho-
racotomy implantable lead systems have now passed from
the initial stage of development, and their value as an ef-
fective method for defibrillation has been confirmed (8-18) .
From the F3ectrophysiology Laboratory, Milwaukee Heart Institute of
Sinai Samaritan Medical Center and St . Luke's Medical Center, University of
Wisconsin-Milwaukee Clinical Campus, Milwaukee, Wisconsin
.
Manuscript received November 29, 1993
; revised manuscript received
February 18, 1994, accepted March 16,1994
.
Address for correspank : Dr. Andrea Natale, 2901 West KK River
Parkway, Suite 470, Milwaukee, Wisconsin 53215
.
01994 by the American College of Cardiology
sic, p
e
0.07) . flip c pulses allowed implantation With
less ventricular fibrillation u (7 .4 ± 3 .2 vs . 3.5 ± 1 .8, p <
0.01) and a mean shorter procedure time (168 ± 39 vs . 111
30 min, p < 0.01) . With the biphasic waveform a greater
i of patients met the implantation criteria with the lead
system (83 vs. 4S%, p < 0.01). When , the left
pre 1 of the patch electrode was alwayssu lent in
patients iv the b1p is device, whereas placement In the
IeR so pular position was required in IS patients in the
group. Implantation of the biphasic device was
ciated with a shorter mean h i stay (3 .8
± 0.8 vs. 5.4 2.2
days, p < 0.01).
Conclasions. Incorporation of a biphasc device in a trans-
venous fm table loverter-defibrillator uniformly Increases
JACC Vol . 24, No . 2
August 1994:406-12
However, although recent developments in defibrillation
pulsing methods and lead systems have led to lower energy
requirements for successful defibrillation, as many as 10 to
30% of patients may still not have reliable defibrillation with
this approach and may require thoracotomy (12-13,16-20) .
In addition, the complexity of the available multilead de-
fibrillation systems may result in extensive intraoperative
testing procedures, resulting in poor patient tolerance
(12,17,20) . Implantable cardioverter-defibrillator systems
lack certain desirable features, and alternate approaches
need to be explored . Experimental data in animal models
and in humans suggest that the biphasic waveform provides
an option for improving defibrillation efficacy (21-27) . How-
ever, experience with permanent implantation of trans-
venous systems that include a biphasic device is limited . In
this study we analyzed the advantage of implanting a nontho-
racotomy defibrillation system connected to a cardioverter-
defibrillator that delivers asymmetric biphasic shocks and
compared the results with those achieved with a standard
device able to deliver monophasic pulses .
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Mode
Patient group . After informed verbal and written consent
for implantation of a transvenous defibrillator was obtained,
91 patients with a history of sudden cardiac death or ven-
tricular tachycardia refractory to antiarrhythmic medica-
tions underwent defibrillator implantation . The patients were
assigned to two different groups and were not randomized to
receive either device ; rather, they were assigned to receive
one of them according to availability . The first group in-
cluded 55 consecutive patients who underwent implantation
and testing using a device capable of delivering monophasic
shocks . The remaining 36 patients underwent implantation
using a hybrid system consisting of the same defibrillating
electrodes that were, however, connected to a device that
allowed defibrillation with asymmetric biphasic pulses . The
presenting arrhythmia was sustained monomorphic ventric-
ular tachycardia in 48 patients, ventricular fibrillation in 29
and both ventricular tachycardia and ventricular fibrillation
in the remaining 14. Coronary artery disease was present in
70 patients, all of whom had a history of previous myocardial
infarction . Two patients had a history of valvular heart
disease ; 15 had dilated idiopathic cardiomyopathy ; and the
remaining four had primary ventricular fibrillation . All 91
patients underwent electrophysiologic study before defibril-
lator implantation. Before electrophysiologic study and de-
fibrillator implantation, antiarrhythmic therapy was dis-
continued for at least five half-lives . All patients were
considered candidates for an irnplantable cardioverter-
defibrillator on the basis of clinical history and the presence
of inducible, sustained monomorphic ventricular tachycar-
dia not responding to antiarrhythmic medications .
Lead system. The transvenous lead system comprised a
12F tripolar endocardial catheter for rate and configuration
sensing, as well as shock delivery . The proximal spring
electrode had a surface area of 617 =2 and the distal spring
electrode a surface area of 295 mm 2 . A porous tip functioned
as the rate-sensing cathode, and the right ventricular spring
electrode served as both the shocking cathode and the
rate-sensing anode. The proximal spring electrode was used
as a cardioversion-defibrillation electrode only . The distal
end of the endocardial lead had tines for passive fixation . To
accommodate different intracardiac proportiotis, two endo-
cardial leads (Endotak-C models 0062 and 0064) were used in
our patients . The proximal electrode positions for models
0062 and 0064 are 13 and 16 cm, respectively, with the
proximal electrode position measured from the distal rate-
sensing tip to the distal end of the proximal electrode . A
patch electrode (CPI model 0063) with a total surface area of
28 cm2 was also available for implantation when bidirec-
tional current pathways were chosen to provide better
defibrillation efficacy. The patch electrode was placed in
either the subcutaneous or submuscular left thoracic wall .
Defibrillation thresholds were tested using either the coillcoil
or the patch/coil configuration. The devices used for perma-
nent implantation included the Ventak 1600, 1550 and 1555
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(CPI) in the first 55 patients, and the Cadence model V-100
(Ventritex, Sunnyvale, CA) was implanted in the remaining
36 patients . All three CPI devices were able to deliver
truncated exponential monophasic shocks, whereas the Vei,
tritex device allowed defibrillation with the asymmetric
biphasic waveform with a programmable pulse width and
shock voltage
. Although the biphasic waveform has an
independently programmable positive and negative pulse
width phase, the negative phase is never allowed to be
programmed longer than the positive phase . According to
the impedance, the pulse width of both positive and negative
phases was chosen to maintain a constant waveform tilt
-65%. With both CPI and Ventritex devices, when bidirec-
tional shocks were needed a 15-cm long AICD-Y connector
(CPI model 6836) was used to connect the endocardial lead
and patch electrodes to the device header.
Device implantation . All implantation procedures were
performed with the patient under general anesthesia. The left
subclavian vein was then cannulated through a 4-cm trans-
verse left infraclavicular incision . Under fluoroscopic guid-
ance, the tripolar endocardiac catheter was passed into the
right ventricular apex, with the proximal spring position at
the junction of the high right atrium and superior vena cava .
The endocardial lead sensing and pacing thresholds were
then measured with a pacing system analyzer . Rate and
configuration sensing lead electrograms were recorded dur-
ing sinus rhythm, as well as during induced ventricular
fibrillation . When the patch electrode was needed, it was
initially placed in the prepectoral left thoracic wall . If this
position did not result in adequate improvement of the
defibrillation threshold, the patient was placed in a 20° left
lateral position, and a 10-cm transverse incision was made at
the left fifth intercostal space crossing the midaxillary line .
At that site the patch electrode was implanted in the sub-
muscular plane deep to the latissimus dorsi and overlying the
serratus anterior muscle .
Fibrillation-defibrillation protocol . Ventricular fibrillation
was induced using 60-Hz alternating current applied through
the rate-sensing electrode . The defibrillation threshold was
then assessed. In the 35 patients undergoing implantation
with the Ventritex device, initial attempts were made with
-18-J shocks delivered through an external defibrillator
(HVS-02, Ventritex) that allowed defibrillation with biphasic
pulses with a programmable pulse width and shock voltage .
If the first shock was successful, the energy of subsequent
fibrillation episodes was decremented by -5 J until failure
was obtained . If the 18-J shock was unsuccessful, further
testing of higher energy using -54 increments was per-
formed until successful defibrillation was achieved. No
energy >35 J was tested . In patients undergoing implanta-
tion with monophasic CPI devices, defibrillation threshold
determination was performed in the same manner . However,
the first defibrillation shock was usually performed using
-20 J. In this cohort defibrillation testing was performed
using an external defibrillator (CPI ECD model 2806)
. Defi-
brillation threshold was defined as the lowest energy of the
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first shock that successfully terminated ventricular fibrilla-
tion. Ten seconds of stable ventricular fibrillation were
allowed before attempting defibrillation
. Before reinduction
of ventricular fibrillation, electrocardiographic and hemody-
namic changes were required to recover . All patients under-
went initial testing using the coil/coil configuration . If this
resulted' in an inadequate defibrillation threshold, the subcu-
taneous patch was then used. With a few exceptions patients
were considered to meet the implantation criteria when the
defibrillation threshold was <25 J with the Ventritex and CPI
1555 devices and <22 J with the CPI 1600 and 1550 genera-
tors. After a lead ca^figuration was chosen for permanent
implantation, the leads were tunneled to the generator
pocket created in the left anterior abdomen. The detection
and termination of induced ventricular fibrillation by the
implanted defibrillator were then tested . The pulse generator
and leads were placed in the abdominal pocket, and the
incisions were closed using reabsorbable sutures .
tatim and follow-up . Before discharge
from hospital, defibrillator testing was performed in all
patients . This included induction of ventricular fibrillation
and ventricular tachycardia. When available, tiered therapy
was programmed according to individual patient character-
istics . Implantable cardioverter-defibrillator evaluation was
repeated 4 to 6 weeks postoperatively . Thereafter, patients
were seen every 3 months or earlier if any shocks were
delivered or if any complications occurred .
ysis. Results are expressed as mean value
±SD. The unpaired Student t test was used to compare
numeric variables in the two patient groups . The chi-square
test was used to compare defibrillation efficacy and other
categoric variables between the two groups ; p < 0.05 was
considered significant .
Results
Clinical characteristics and demographic data for both
group of patients are summarized in Table 1 . Between the
two groups there was no difference in terms of age, gender,
distribution, mean ejection fraction and type of underlying
structural heart disease . Although a slightly higher propor-
tion of patients in the group receiving the biphasic device
had sustained inducible monomorphic ventricular tachycar-
dia, this did not prove statistically significant . In patients
receiving the biphasic device, mean age was 64 ± 10 years
(range 38 to 79), mean ejection fraction was 29 ± 10%, and
64% had inducible sustained monomorphic ventricular
tachycardia at preimplantation electrophysiologic study .
Previous antiarrhythmic drug therapy ranged from zero to
three drug trials. Before implantation, all antiarrhythmic
medications were discontinued for at least five half-lives .
Two patients underwent implantation while still receiving
amiodarone therapy . Similarly, in the 55 patients undergoing
testing and implantation with the monophasic device, mean
age was 62 ± 12 years (range 28 to 78), mean left ventricular
ejection fraction was 28 ± 11%, and 30 patients (54%) had
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Table I . Demographic Data and Clinical Characteristics of the
Two Groups of Patients Undergoing Implantation
Data presented are mean value ± SD or number %) of patients . DC =
dilated cardiomyopathy ; El' = ejection fraction ; k = female ; IHD = ischemic
heart disease
; IVF = idiopathic ventricular fibtillaai
e:°.11
= male; VHD =
valvulaar heart disease ; VT-S (inducible) = inducible, sustained monomorphic
ventricular tachycardia
.
inducible sustained monomorphic ventricular tachycardia at
preimplantation electrophysiologic study . As in the previous
group, before defibrillator implantation unsuccessful antiar
rhythmic drug therapy ranged from zero to four trials . In this
group, only one patient had amiodarone therapy at implan-
tation; two additional patients underwent implantation 3
weeks after amiodarone was discontinued .
Implant data. With the same defibrillating lead system
the biphasic device was successfully implanted in all 36 pa-
tients (10D%) in whom it was attempted ; successful implanta-
tion was possible only in 49 (89%) of 55 patients receiving the
standard monophasic device (p = 0 .07) (Table 2) .
Electrode configurations used in the 85 patients able to
receive a permanent implant are presented in Table 3 . In 30
(83%) of 36 patients receiving the biphasic device, the
configuration with the lead alone allowed adequate defibril-
lation thresholds. Of these, 10 patients had better defibrilla-
tion efficacy using a reverse polarity, namely, the superior
vena cava coil as cathode and the right ventricular coil as
anode. In the remaining six patients the patch electrode was
Table 2 . Implant Data Relative to Patients Who Received
Permanent Implants With the Transvenous System in the
Two Groups
Data presented are mean value ± SD or number (%) of patients . Hospital
stay = mean hospital stay in patients receiving permanent implants ; Mean
DFT = mean defibrillation threshold ; Success rate = permanent implantation
with transvenous system ; VF induction = mean ventricular fibrillation induc-





Success rate 36136 49/55 0.07
(100%) (89%)
Mean DFT (J) 12 ± 5 15 ± 4 .7 0.03
VF induction (n) 3.5 ± 1 .8 7 .4 ± 3 .2 < 0.01
Implantation time (min) 111 ± 30 168 ± 39 < 0.01






(n = 55) p Value
Age (yr) 64 ± 10 62 ± 12 NS
Gender (M/F) 25/11 37/18 NS
EF (%) 29 ± 10 28 } 11 NS
VT-S (inducible) 23(64%) 30(547c) NS
lHD 29 41 NS
DC 6 9 NS
VHD --- 2 NS
IVF I 3 NS
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Table 3 . Configuration Data for 85 Patients Receiving a Permanent Implant
Pis = patients; RV = right ventricular coil ; SQ = subcutaneous patch ; SVC = superior vena cava coil
.
required, and in all six it was placed in the left prepectoral
position using the incision through which cannulation of the
left subclavian vein was obtained. In these six patients
defibrillation threshold ranged from 10 to 20 J .
Among the 49 patients who met the implantation criteria
for the monophasic device, only 22 (45%) achieved an
acc,ntable defibrillation threshold with the lead alone (45%
morkophasic vs . 83% biphasic, p < 0.01). However, only two
patients received permanent implants using the single-lead
configuration, whereas in the remaining 20 a left prepectoral
patch electrode was used to lower the defibrillation threshold
and obtain a larger safety margin (14 .6 ± 5 J vs . 21 ± 3 .4 J,
p < 0.01). In the remaining 27 patients the lead alone did not
satisfy the defibrillation threshold implant criteria, and a
subcutaneous patch was required . In 15 of these patients a
left posterior subscapular patch electrode position was nec-
essary to obtain a defibrillation threshold within an accept-
able range . Placement of the subcutaneous patch in the latter
position involved an additional surgical incision . In the
remaining 12 patients a left anterior prepectoral location of
the patch electrode was sufficient to achieve a lower defi-
brillation threshold .
The mean total time in the operating room for implanta-
tion in the group receivinn the monophasic device with the
transvenous system was 168 ± 39 min ; the implantation
procedure could be terminated within a mean total time of
111 ± 30 min in patients undergoing implantation with a
biphasic device (p < 0.01) .
Defibrillation threshold data. Among patients undergoing
implantation with the nonthoracotomy lead system, the
measured delivered energy defibrillation threshold obtained
with the final lead configuration at implantation was signifi-
cantly lower with the biphasic than monophasic pulse (12 t
5 J vs. 15 ± 4.7 J, p = 0.03) . Similar results were obtained
comparing the stored energy defibrillation threshold . Mean
pulse width for the monophasic waveform was 6.6 ± 1 .2 ins,
whereas that including both positive and negative phases of
the biphasic 65% tilt waveform was 14 .8 ± 1 .6 ms. There
was no significant difference in the lead system impedance
with the two waveforms (biphasic 46 ± 4 .9 ohms vs .
monophasic 44 ± 8 ohms, p = NS) .
Although direct comparison between biphasic and
monophasic pulses in the same patient was not prospectively
performed, in nine patients receiving the biphasic device,
NATALF ET AL
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monophasic shocks with leads alone were also tested . In
seven of them, a biphasic waveform resulted in higher
defibrillation efficacy with respect to monophasic pulses . In
the remaining two patients, similar defibrillation thresholds
were obtained with both biphasic and monophasic wave-
forms. In three additional patients undergoing permanent
implantation with the biphasic device using the negative
right ventricular coil, positive superior vena cava coil,
positive subcutaneous patch configuration, simultaneous bi-
directional monophasic shocks did not achieve defibrillation
with the highest energy tested at 35 J in two patients and
provided a defibrillation threshold of 28 J in the third patient .
In the same patients simultaneous biphasic pulses achieved
defibrillation thresholds of 18, 15 and 10 J, respectively .
The number of configurations tested in the biphasic group
ranged from one to four (mean 1 .6 ± 0.8) ; in the other group
undergoing testing with the monophasic device, one to eight
(mean 3.6 ± 1 .3, p < 0 .01) different lead configurations were
tested . Similarly, the mean number of ventricular fibrillation
inductions required to determine the successful configura-
tion for permanent implantation was significantly higher in
the monophasic waveform group, at 7 .4 ± 3.2 versus 3.5 ±
1 .8 inductions in the biphasic waveform group (p < 0 .01) .
Six patients in the monophasic device group did not satisfy
the implantation criteria and underwent permanent implan-
tation using an epicardial defibrillation system placed
through a left lateral thoracotomy . None of these patients
was receiving amiodarone therapy at implantation . No ready
explanation for the high defibrillation threshold energy could
be found in any of these patients . Data relative to these
patients were not included in the analysis of the monophasic
group variables .
Postoperative course,. All patients tolerated the implanta-
tion procedure without difficulty, and there were no periop-
erative complications or deaths in both groups . All 36
patients receiving the biphasic device were awake and
extubated in the operating room at the end of the operation .
In addition, all of these patients were able to ambulate within
24 h, and none experienced prolonged discomfort because of
the procedure . Mean hospital stay in this group was 3 .8 ±
0.8 days . Similarly, in the other group the immediate post-
operative course was relatively uneventful . However, in six
patients who received more extensive testing during the
intraoperative procedure, extubation was delayed, and a
Endotak Biphaiic Configuration
Endotak Monophasic Configuration
No. of Pis Cathode Anode Anode No . of Pts Cathode Anode Anode
20 RV Svc
45 RV Svc
to SVC RV RV
Svc
5 RV SVC SQ SVC RV SQ
I SVC RV SQ
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24-h stay in the intensive care unit was required because of
hemodynamic instability . Mean hospital stay in this group
was 5.4 ± 2.2 days (p < 0 .01)
. Three patients in the
monophasic device group developed hematoma at the site of
the subcutaneous patch . One of these patients received
anticoagulation 24 h-after the procedure because of a recent
history of deep venous thrombosis . All three patients had the
patch electrode located in the. left posterior subscapular
position . One of them required intervention
. Usually, when
the left posterior patch was used, patients required longer
therapy with analgesic medications to relieve discomfort
(3.6 ± 1 .2 vs. 7 ± 3.2 days, p < 0.01)
. All 85 patients receiv-
ing a transvenous system underwent predischarge and
[-month cardioverterdefibrillator testing, including induc-
tion of ventricular fibrillation and ventricular tachycardia . In
none of these patients was a significant increase in ventric-
ular defibrillation threshold energy observed . In the group
receiving the biphasic device, the longer follow-up period
was 5 months; the mean follow-up among the 49 patients
with the sta tdard monophasic device was 24 ± 8 .8 months .
In the latter group, during the follow-up period, one patient
experienced sudden death after receiving multiple firing from
Fate device, and four additional patients died of congestive
heart failure . No evidence of lead dislodgment occurred in
all 85 patients .
Discussion
The use of the automatic implantable cardioverter-
defibrillator in patients with sudden cardiac death or recur-
rent sustained monomorphic ventricular tachycardia has
drastically changed our theraper approach to this patient
population and has also improved the survival rate of this
cohort. Despite its efficacy, initial experience with the epi-
cardial defibrillating system has been associated with a
perioperative mortality rate as high as 8% (10,15,28-31) .
Nonthoracotomy lead systems were proposed and intro-
duced to minimize the overall surgical risk associated with
defibrillator implantation and to maximize the overall benefit
of this procedure (8-18) . After several years of experience,
the feasibility of different nonthoracotomy lead systems with
respect to reducing overall perioperative risks and demon-
strating adequacy of defibrillation threshold has been docu-
mented. However, although it appears that the reliability of
a nonthoracotomy lead system has become a reality, several
problems remain unsolved .
Previous data with mono systems. As suggested by
previous investigations, even though testing of multiple
combinations of lead systems and pulsing methods may
ultimately provide an adequate safety margin for defibrilla-
tion in the majority of patients, this involves extensive
testing using different pulsing techniques, various defibrilla-
tion lead combinations and changes of polarity (12,17-
18,20,26). When a triple-lead defibrillating system is used,
altering these variables may result in >20 different combi-
nations to be tested (17,20). The complexity of such a system
raises important concerns with regard to patient safety and
has also made it difficult to establish guidelines for lead
placement and to determine the relative efficacy of various
lead configurations. From a practical standpoint, however,
finding an acceptable configuration in an individual patient
may be limited by the excessive amount of defibrillation
testing required . Although certain pulsing methods and
electrode positions will have a higher likelihood of success
than others (20,32-33), there is currently no way to predict
the optimal system in an individual subject without extensive
testing . Finally, as su ested by several reports, the relative
benefit achieved by testing the myriad of lead combinations
or permutations possible is still nut satisfactory, and in 10%
to 30°% of the patients, acceptable defibrillation efficacy is
not achieved (12.14,16-20). Undoubtedly, thrre is a need for
a more effective energy waveform. In addition, the ideal
nonthoracotomy defibrillator lead system must also be sim-
pler to evaluate and implant .
Benefits of a biphasic device . In our study the use of a
hybrid system that combined the Endotak lead with a device
able to deliver asymmetric biphasic pulses increased the rate
of successful implantation and remarkably shortened the
implantation procedure time, minimizing intraoperative test-
ing. In fact, although in all 91 patients the defibrillation lead
system initially tested was the same, the sole use of a
biphasic pulse generator allowed an increase in defibrillation
efficacy from 89%'0 to 1 .1%0 . In addition, in our experience a
larger proportion of patients was able to receive permanent
implantation with the lead alone when biphasic shocks were
used. Moreover, when the subcutaneous patch was needed
to achieve better defibrillation efficacy, placement of this
electrode in the left posterior chest wall was necessary in
none of the subjects, which spared the patient an additional
surgical incision. However, in the group undergoing perma-
nent implantation with a device that incorporates monopha-
sic pulses only, placement of the patch electrode in the left
posterior thoracic wall was required in a conspicuous num-
ber of patients .
Although we do not have long-term follow-up in the
patients receiving permanent implantation with a biphasic
device, all of these advantages can potentially reduce com-
plications related to multiple testing and additional electrode
placement and surgical procedures, such as infection, hema-
toma, lead-related malfunction and hemodynamic instabil-
ity. This may account for the short r average hospital stay
required after implantation of the biphasic device . In our
institution, we previously showed that implantation of the
Endotak system required a significant lower time than did an
alternative triple-lead defibrillating system (34) . This proba-
bly reflected the lower number of leads to be implanted and
a device with fewer alternative pulsing methods to test .
Despite this, the larger total surface area available in the
Endotak system provided defibrillation efficacy as high as
that achieved with the triple-lead system . In the present
study incorporation and testing of the biphasic waveform
.!ACC Vol . 24, No. 2
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appeared to reduce further the procedure time and the
number of ventricular fibrillation trials required to determine
the successful configuration for permanent implantation .
This study did not compare the defibrillation efficacy
achieved with the biphasic waveform with that achieved by
the monophasic waveform in individual patients. However,
when testing of both waveforms was performed, it appeared
that the biphasic shocks could enhance defibrillation efficacy
it patients refractory to single and bidirectional monophasic
shocks . Concern has been expressed that a limited safety
margin in patients with a high defibrillation threshold at
implantation might influence the subsequent sudden cardiac
death rate in this cohort . Our experience clearly suggested
that biphasic shocks not only increase defibrillation efficacy
and abbreviate intraoperative testing, but they also provide a
larger safety margin that might be of particular importance in
patients requiring additional antiarrhythmic treatment
. Our
results are similar to those reported by Saksena et al . (26)
using a triple-lead system . The slightly higher successful
defibrillation rate reported in our study might be related to
the larger surface area of the defibrillating system used in our
patients
. The reason for a better defibrillation efficacy with
biphasic waveform cannot be explained on the basis of our
study . In addition, different biphasic waveform shapes might
further improve defibrillation efficacy, and this needs further
investigation (35-37) . However, as shown in our study, the
use of biphasic shocks as the waveform of initial choice
eliminates the need for a multitude of ventricular fibrillation
inductions, obviating the need for a prolonged defibrillation
threshold testing and implantation procedure . Furthermore,
the lower defibrillation energy requirement obtained with the
biphasic waveform ultimately might facilitate more wide-
spread use of this technology and increase the proportion of
patients who are candidates for permanent implantation with
a transvenous defibrillation lead system . Despite such en-
couraging results, this improvised defibrillating system con-
stitutes an off-label use of approved, commercially available
hardware. This raises legitimate concerns with regard to the
hypothetic higher potential for some component failure . In
view of these concerns, it may be misleading to equate the
feasibility of this approach with its long-term function.
Conclusions. Although longer follow-up is needed to es-
tablish the long-term stability and efficacy of this system,
and although the use of a hybrid cardioverter-defibrillator is
disputable, the biphasic waveform has the potential to ex-
pand the acceptability of the presently available transvenous
defibrillation system, to minimize the complexity of the
implantation procedure and to provide the appropriate min-
imal energy requirement for defibrillation in the majority of
defibrillator recipients .
We gratefully appreciate the excellent work of Chris Martin and Susan
Ulatowski in preparing the manuscript .
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